MGMT methylation as a predictor of efficacy of temozolomide and capecitabine in metastatic colorectal cancer

MD, professor
Per Pfeiffer
Department of Oncology, Odense university Hospital

Project management

Project status	Open



Data collection dates
Start	15.01.2025
End	01.02.2027

Project in numbers

OPEN survey/clinical data
Expected # of participants	80
Included # of participants





Included participants with specimens
Specimens

MGMT methylation as a predictor of efficacy of temozolomide and capecitabine in metastatic colorectal cancer

Short summary

Between 2013-2016 we treated 82 patients with metastatic colorectal cancer with temozolomide and capecitabine in a phase 2 study. We wish to investigate whether methylation/silencing of the MGMT gene is a predictor for efficacy of this treatment combination, by analyzing archived tumor tissue from the patients in the phase 2 study.

Data and biological material

Data on survival (PFS, OS), adverse events and methylation of MGMT on tumor tissue.

Collaborating researchers and departments

Department of clinical Pahology, Odense University Hospital,